by xio | Jan 23, 2026 | Uncategorized
Why Speed Matters in Allogeneic Cell Therapy Fill & FinishAnd how faster filling protects product quality, reduces risk, and improves scalabilityAs allogeneic (“off the shelf”) cell therapies continue to expand, manufacturing teams face a clear challenge: produce...
by xio | Jan 23, 2026 | Uncategorized
As tissue banking continues to scale, precision and consistency are becoming just as critical as compliance. Whether processing dermis, amnion, or other soft tissues, banks are being asked to deliver uniform grafts while operating under tighter cleanroom controls and...
by Sydney Braun | May 14, 2025 | Uncategorized
Cell and gene therapy developers continually encounter significant hurdles during the fill & finish phase—challenges best illustrated by manual workflows that are prone to variability, risk of contamination, and limited scalability. This whitepaper, authored by...
by Sydney Braun | Dec 30, 2024 | Uncategorized
This summary is based on the original article, which can be found here. Cellipont Bioservices, a contract development and manufacturing organization (CDMO) specializing in cell therapy manufacturing, has entered into a strategic partnership with Xiogenix, a...
by Sydney Braun | Dec 30, 2024 | Uncategorized
This summary is based on the original press release, which can be found here. Xiogenix, a leader in biopharmaceutical technology, is excited to announce a strategic partnership with Cellipont Bioservices, a premier cell therapy Contract Development and Manufacturing...
by xio | Jul 29, 2023 | Uncategorized
In recent years, a remarkable revolution in cancer treatment has taken center stage, captivating the medical community and offering hope to millions of patients and their families. Chimeric Antigen Receptor T-cell therapy, commonly known as CAR-T therapy, has emerged...
